The Impact of Liposomal Irinotecan on the Treatment of ... | 合法藥品大搜索

由YYSu著作·2020·被引用4次—Liposomalirinotecanplus5-fluorouracil/leucovorin(nal-IRI+5-FU/LV)hasshowntoprovidesurvivalbenefitsforpatientswith ...

Current study shows that nal-IRI + 5-FU/LV regimen could achieve a 9.1% of response rate and 6.6 months of overall survival for gemcitabine-refractory advanced PDAC on intent-to-treat analysis in a real-world Taiwanese cohort, including 27.3% ECOG PS > 2 patients and 65.9% having reduced initial dose of nal-IRI to 60 mg/m2. The treatment outcomes largely concur with those of pivotal NAPOLI-1 trial in which most patients were ECOG PS 0-1 and had standard starting dose of 80 mg/m2 nal-IRI16. After excluding those with ECOG PS > 2, the median OS of our ECOG PS 0-1 cohort was 7.8 months, which was compatible with that of 8.9 months in Asian subgroup of NAPOLI-124. To the best of our knowledge, the clinical outcomes of ECOG PS > 2 patients receiving nal-IRI + 5-FU/LV remains yet illustrated, in neither previous reports from the Memorial Sloan Kettering Cancer Center (MSKCC) and NAPOLI-1 studies that includin...